Navigation Links
Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
Date:11/5/2007

1200 Q4w

treatment group achieved SVR, vs. 57.9% for peginterferon alfa-2a

administered every week.

-- In heavier patients (75 kg or heavier) who were treatment-adherent,

61.0% of those in the Albuferon 1200 Q4w treatment group achieved SVR,

versus 53.3% for peginterferon alfa-2a administered once every week.

-- Among all treatment-adherent patients in the Albuferon 1200 Q4w

treatment group, 62.0% achieved SVR, versus 66.7% for peginterferon

alfa-2a.

-- The rate of discontinuations due to adverse events was 12.1% in the

Albuferon 1200 Q4w treatment group, vs. 6.1% in the peginterferon alfa-

2a group. Adverse events observed were those typically expected with

interferon therapy.

-- The number of patients experiencing severe hematologic adverse events

was significantly lower in the Albuferon 1200 Q4w treatment group

(10.3%, vs. 20.2% for peginterferon alfa-2a, p<0.05).

Higher doses of Albuferon administered every four weeks, in combination with ribavirin, will be explored in a separate Phase 2b trial conducted by Novartis, which is expected to begin by year-end 2007.

About Albuferon

Albuferon is a novel long-acting form of interferon alpha created by HGS using its proprietary albumin fusion technology. Albuferon results from the genetic fusion of human albumin and interferon alpha. Human albumin is the most prevalent naturally occurring blood protein in the human circulatory system, persisting in circulation in the body for more than 20 days. Research shows that genetic fusion of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of the proteins. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B and a number of cancers.

Albuferon is being developed by HGS and Novartis for the treatment of chronic hepatitis C under a worldwide co-development and commerci
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)...   Intarcia Therapeutics, Inc. today announced the ... an equity conversion option at a $5.5 billion Company ... the initiation of additional head-to-head comparative and switch studies ... 2 diabetes therapies. In addition, proceeds from the financing ... launch ITCA 650 in the United States ...
(Date:4/27/2015)... 2015 Array BioPharma Inc. (Nasdaq: ... third quarter of fiscal 2015 and hold ... on Monday, May 4, 2015.  Ron Squarer, ... May 4, 2015Time:9:00 a.m. Eastern TimeToll-Free:(844) 464-3927Toll:(765) ... Conference Call Slides:  http://edge.media-server.com/m/p/8tsxszuw/lan/en ...
(Date:4/27/2015)... THE WOODLANDS, Texas , April 27, 2015 /PRNewswire/ ... a biopharmaceutical company focused on developing breakthrough treatments for ... results on Wednesday, April 29, 2015 after the financial ... and webcast to discuss clinical development progress and financial ... Eastern Time on April 29, 2015. The ...
Breaking Medicine Technology:Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuation 2Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuation 3Lexicon To Report First Quarter 2015 Financial Results On April 29, 2015 2
(Date:4/28/2015)... 28, 2015 A new survey from ... lung damage, 66 percent of Americans fear brain damage the ... Awareness Month in May, shed light on the need for ... help prevent a stroke. By controlling modifiable risk factors, ... stroke is a “ brain attack ” that occurs when ...
(Date:4/28/2015)... Hellen Chen, who is a bestselling author ... According to a study conducted by Washington University, ... 30 has increased by 20% while the number of unfaithful ... a report released this year from the Journal ... one or both spouses admit to infidelity, either physical or ...
(Date:4/28/2015)... Seattle, WA (PRWEB) April 28, 2015 It’s ... of Paul L. Schneiderman . For Schneiderman, a civil litigation ... a legal analyst on TV and radio networks, it’s also ... the Seattle native recently joined the Fred Hutchinson Cancer Research ... of work to do in the community, and lawyers can ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 Enrollment ... dual eligibles reached 2.2 million in April, according ... (AIS) new Medicare-Medicaid Dual Eligibles Database , ... and plans serving the dual-eligible community. This is ... Database began tracking initiatives in January, but only ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 The Awareness Counselor ... the common topic of judging. According to Awareness Counselor, there ... people, when directed outward, and to an individual who self-judges. ... new clients as a class or one one one talk. ... founder of Awareness Counselor, is that every being on earth ...
Breaking Medicine News(10 mins):Health News:National Stroke Association Survey Reveals Americans Fear Brain Damage the Most, but Few Take the Necessary Steps to Prevent a Stroke 2Health News:National Stroke Association Survey Reveals Americans Fear Brain Damage the Most, but Few Take the Necessary Steps to Prevent a Stroke 3Health News:Why Do Some Good Women and Men End Up Breaking Others' Marriages? 2Health News:Why Do Some Good Women and Men End Up Breaking Others' Marriages? 3Health News:Seattle Attorney Paul Schneiderman Helping to Combat Cancer 2Health News:Enrollment in Duals Programs Increases 14%, New AIS Database Finds 2Health News:What Happens When We Judge Ourselves and Others? – A New Concept Introduced 2Health News:What Happens When We Judge Ourselves and Others? – A New Concept Introduced 3
... to protect people against eating disorders, providing further evidence ... -- are linked to anorexia and bulimia, according to ... ongoing, six-year study of 538 sets of twins in ... with male twins have lower risk for eating disorder ...
... without approval , , MONDAY, March 3 (HealthDay News) ... prescription drugs increases the risk of drug abuse, says ... McCabe asked 3,639 college students, average age 19.9 years, ... of prescription drugs -- opioids, stimulants, sleeping aids and ...
... Management" or the "Company") (OTC: SMAN, SMANP), an,Indianapolis-based ... 14C,Information Statement pursuant to Section 14C of the ... directors approved an amendment to,increase the number of ... to 300,000,000 shares. In connection therewith, a resolution,will ...
... Assembly Bills Protecting State,s,Elderly from Price Gouging, ... March 3 California,seniors who feel price-gouged ... up with advocates and elected leaders to ... address serious problems with emergency,preparedness. Legislation introduced ...
... of Catholic Bishops (USCCB) welcomes the House Committee ... bipartisan bill to combat,HIV/AIDS, tuberculosis and malaria. House ... G. Wenski of Orlando, Florida, chairman of the ... Justin Rigali of,Philadelphia, chairman of the Committee on ...
... For the first,time, Beauty.com, Inc., a wholly owned ... Los Angeles-based women,s wear designer Jenni,Kayne to create a ... clutch. Customers receive the limited edition designer bag,filled with ... beauty,brands with a purchase of $75 or more on ...
Cached Medicine News:Health News:MSU research indicates testosterone could guard against eating disorders 2Health News:Non-Medical Use of Prescriptions Linked to Drug Abuse Risk 2Health News:Standard Management Seeks Additional Shares 2Health News:'Atria Bills' Get Support From Assisted Living Residents, Family Members, Senior Groups 2Health News:Catholic Bishops Welcome New Bill for Global HIV/AIDS Relief 2Health News:Beauty.com Partners With Fashion Designer Jenni Kayne 2Health News:Beauty.com Partners With Fashion Designer Jenni Kayne 3Health News:Beauty.com Partners With Fashion Designer Jenni Kayne 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: